
Stendra Enhances Erectile Function in American Males with Neurogenic ED: Trial Results
Reading Time: 2 minutes Introduction Erectile dysfunction (ED) is a prevalent condition that affects a significant portion of the American male population, particularly those with neurological disorders. Neurogenic ED, resulting from nerve damage due to conditions such as multiple sclerosis, spinal cord injury, or diabetic neuropathy, presents a unique challenge in treatment. Stendra (avanafil), a phosphodiesterase type 5 (PDE5) inhibitor, has emerged as a promising therapeutic option. This article discusses the findings of a randomized, controlled trial evaluating the efficacy of Stendra in American males with neurogenic ED, incorporating detailed neurological assessments. Study Design and Methodology The trial was designed as a double-blind, placebo-controlled...